Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 15, 2016

Deals this week: Applied BioMath, Mironid, ApoGen Biotechnologies

Applied BioMath and Tusk Therapeutics NV have entered a co-development agreement to quantify and analyse the drug properties and select pre-clinical drug candidates within immuno-oncology.

Applied BioMath and Tusk Therapeutics NV have entered a co-development agreement to quantify and analyse the drug properties and select pre-clinical drug candidates within immuno-oncology.

Pursuant to the agreement, the two partners will work on developing quantitative system pharmacology (QSP) model for a Tusk Therapeutics’ target and antibody candidates using Applied BioMath’s mechanistic modelling platform.

The agreement allows the two partners to develop pre-clinical drug candidate selection.

Mironid and the University of Sheffield have entered a collaboration agreement to develop new therapeutics for Autosomal Dominant Polycystic Kidney Disease (ADPKD).

As part of the agreement, the two partners will jointly advance the clinical development of Mironid’s LoAc molecules.

The agreement enables the partners to produce new therapies for ADPKD.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
"Mironid and the University of Sheffield have entered a collaboration agreement to develop new therapeutics for Autosomal Dominant Polycystic Kidney Disease (ADPKD)."

ApoGen Biotechnologies has raised $7m in a series A financing round, which was led by Accelerator Corporation and co-led by AbbVie Biotech Ventures, Alexandria Ventures Investments, ARCH venture Partners, Eli Lilly and Company and Johnson & Johnson Innovation.

The company plans to invest the funds to develop novel drugs to target resistance to cancer therapy.

Achaogen plans for an underwritten public offering of 6.5 million shares of its common stock.

The company expects to raise $87.75m through the offering, which is expected to be completed by 19 December.

Latham & Watkins is acting as the legal advisor for the offering.

The company intends to invest the funds to advance the development, marketing and commercialisation of Plazomicin and fund a variety of capital preservation investments.

Enumeral Biomedical Holdings has raised $3.4m through the private placement of 6.8 million shares of warrants.

The company plans to use the funds for its ongoing operations and for general corporate purposes.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU